In this presentation, we explore the growing role of artificial intelligence (AI) in clinical development, with a particular focus on relations between the design and optimization of clinical trials and intellectual property.AI is increasingly being used to identify new therapeutic options or improve on therapeutic aspects in preclinical and clinical developments. At the same time, these AI-supported innovations have raised new questions regarding intellectual property (IP) protection, and the legal frameworks are evolving gradually to adapt to these AI-assisted inventions.